National Asset Management Inc. boosted its position in shares of Livongo Health, Inc. (NASDAQ:LVGO) by 18.6% in the third quarter, Holdings Channel.com reports. The firm owned 27,463 shares of the company’s stock after acquiring an additional 4,316 shares during the period. National Asset Management Inc.’s holdings in Livongo Health were worth $2,319,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LVGO. Vanguard Group Inc. lifted its holdings in Livongo Health by 101.5% in the 2nd quarter. Vanguard Group Inc. now owns 4,210,399 shares of the company’s stock worth $316,579,000 after buying an additional 2,120,427 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its position in shares of Livongo Health by 87.8% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,676,694 shares of the company’s stock worth $126,071,000 after acquiring an additional 783,726 shares during the last quarter. State Street Corp increased its position in shares of Livongo Health by 257.6% during the first quarter. State Street Corp now owns 927,891 shares of the company’s stock worth $26,473,000 after acquiring an additional 668,404 shares during the last quarter. Ardevora Asset Management LLP acquired a new position in shares of Livongo Health in the second quarter worth about $48,254,000. Finally, ARP Americas LP purchased a new position in Livongo Health in the third quarter valued at about $61,614,000. 41.67% of the stock is owned by institutional investors and hedge funds.
In other Livongo Health news, CFO Lee Shapiro sold 84,132 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $124.50, for a total value of $10,474,434.00. Following the sale, the chief financial officer now owns 1,810,499 shares in the company, valued at $225,407,125.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Glen Tullman sold 422,000 shares of Livongo Health stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $124.50, for a total value of $52,539,000.00. Following the sale, the chairman now directly owns 1,348,199 shares in the company, valued at approximately $167,850,775.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 691,865 shares of company stock worth $86,180,389. Corporate insiders own 13.00% of the company’s stock.
Shares of Livongo Health stock remained flat at $$139.77 on Tuesday. The firm has a market cap of $14.20 billion, a PE ratio of -349.42 and a beta of 1.81. Livongo Health, Inc. has a one year low of $18.76 and a one year high of $151.05. The company has a quick ratio of 19.51, a current ratio of 19.88 and a debt-to-equity ratio of 0.69. The company’s 50-day simple moving average is $140.70 and its 200 day simple moving average is $106.39.
Livongo Health (NASDAQ:LVGO) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.11. Livongo Health had a positive return on equity of 0.29% and a negative net margin of 12.20%. Equities research analysts forecast that Livongo Health, Inc. will post -0.06 earnings per share for the current year.
The company also recently declared a dividend, which was paid on Tuesday, November 3rd. Stockholders of record on Thursday, October 29th were given a dividend of $7.09 per share. The ex-dividend date of this dividend was Monday, November 2nd.
Several research firms have issued reports on LVGO. Benchmark downgraded Livongo Health from a “buy” rating to a “hold” rating in a report on Friday, August 7th. BidaskClub lowered shares of Livongo Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 13th. Needham & Company LLC reiterated a “hold” rating on shares of Livongo Health in a research note on Thursday, October 29th. KeyCorp raised their price objective on shares of Livongo Health from $153.00 to $156.00 and gave the stock an “overweight” rating in a report on Thursday, October 29th. Finally, Canaccord Genuity upped their target price on shares of Livongo Health from $110.00 to $139.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $106.29.
Livongo Health Profile
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
See Also: Trade War
Want to see what other hedge funds are holding LVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Livongo Health, Inc. (NASDAQ:LVGO).
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.